viewSUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals appoints public company specialist Phillip Hains as company secretary

The company completed a heavily oversubscribed entitlement offer to raise $3.56 million on August 5 with Baker Young as the lead manager.

SUDA Pharmaceuticals Ltd - Suda Pharmaceuticals appoints Phillip Hains as company secretary effective from July
Funds raised from the recent placement will be used to supplement working capital

SUDA Pharmaceuticals Ltd (ASX:SUD) has appointed public company specialist Philip Hains as company secretary with the change coming into effect on July 1.

Hains, who is a chartered accountant operating a specialist public practice The CFO Solution, has served the needs of several company boards and their related committees

He has more than 25 years' experience in providing businesses with accounting, administration, compliance and general management services.

Hains holds a Master of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants.

Invaluable contributions

Joseph Ohayon, who joined the company in July 2010, held the role as company secretary from March 2011 and had been a director of the company from December 2012 until May 2019.

He has assisted in the transition of accounting and company secretarial services to The CFO Solutions and supported CEO and managing director, Dr Michael Baker, since he joined at the beginning of the year.

Ohayon will be leaving the company at the end of September.

During his time at SUDA, he has provided invaluable contributions to the company and the team at SUDA has wished him all the best for his new endeavours.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.041 AUD

Market: ASX
Market Cap: $12.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...


Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead...

Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive's Andrew Scott soon after announcing they've received Therapeutics Goods Administration (TGA) approval for their lead product ZolpiMist for the treatment of short-term insomnia in adults. Baker says it's a...

on 31/7/20

2 min read